跳至主要内容
临床试验/JPRN-UMIN000017895
JPRN-UMIN000017895已完成未知

Investigation on Efficacy and Safety of Apixaban in Japanese Elderly Patients: Investigator-Initiated Multicenter Prospective Cohort Study - J-ELD AF (CVI ARO 5) Study

The Cardiovascular Institute Academic Organization (CVI ARO)0 个研究点目标入组 3,031 人开始时间: 2015年6月13日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
3,031

研究概览

简要总结

Event rates (/100 person-years) in standard and reduced dose groups were 1.67 and 1.56, respectively, for stroke or systemic embolism, 1.42 and 2.25 for bleeding requiring hospitalization, 1.41 and 4.46 for total death, and 0.41 and 1.36 for cardiovascular death.

研究设计

研究类型
Observational

入排标准

年龄范围
75years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Apixaban hypersensitivity (2) Clinically significant bleeding (3) River dysfunction with clotting disorder (4) Renal dysfunction (creatinine clearance <15 mL/min) (5) Mitral stenosis and prosthetic valve (6) Inadequate dosage of apixaban at registration (2.5 mg twice a day for those without indications for reducing dose, or 5 mg twice a day for those with them) (7) Patients who did not give written informed consents for this study (8) Venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism) (9) Patients who are judged by the researchers as inadequate for this study

研究者

发起方
The Cardiovascular Institute Academic Organization (CVI ARO)

相似试验